Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum
This article was originally published in The Pink Sheet Daily
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.
You may also be interested in...
Survey Says: Diabetes The Top Category Targeted For Managing Spend
Health plans are looking to curb diabetes drug spending, with the therapeutic area being called out as the number one or two category for managing drug spend in a survey of payers conducted by Leerink.
Express Scripts' 2016 Formulary Continues Exclusion Of Gilead’s Harvoni
The pharmacy benefit manager released its national preferred formulary for 2016. AbbVie’s Viekira Pak remains the preferred alternative for hepatitis C, while Harvoni remains blocked from coverage.
Novo Nordisk CEO: Outcomes-Based Contracts For Diabetes ‘Problematic’
In interview with “The Pink Sheet,” Lars Sorensen discusses the pricing and rebating environment for diabetes drugs and the company’s attitude toward exclusionary formularies.